Literature DB >> 26764527

A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.

Kami Maddocks1, Erin Hertlein1, Timothy L Chen2, Amy J Wagner2, Yonghua Ling3, Joseph Flynn1, Mitch Phelps3, Amy J Johnson1, John C Byrd1,4, Jeffrey A Jones1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26764527      PMCID: PMC5455147          DOI: 10.3109/10428194.2015.1129536

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


× No keyword cloud information.
  11 in total

1.  17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition.

Authors:  Erin Hertlein; Amy J Wagner; Jeffrey Jones; Thomas S Lin; Kami J Maddocks; William H Towns; Virginia M Goettl; Xiaoli Zhang; David Jarjoura; Chelsey A Raymond; Derek A West; Carlo M Croce; John C Byrd; Amy J Johnson
Journal:  Blood       Date:  2010-03-29       Impact factor: 22.113

2.  Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma models.

Authors:  Tomoko Smyth; Kim H T Paraiso; Keisha Hearn; Ana M Rodriguez-Lopez; Joanne M Munck; H Eirik Haarberg; Vernon K Sondak; Neil T Thompson; Mohammad Azab; John F Lyons; Keiran S M Smalley; Nicola G Wallis
Journal:  Mol Cancer Ther       Date:  2014-10-27       Impact factor: 6.261

3.  The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non-small cell lung cancer.

Authors:  Brent Graham; Jayne Curry; Tomoko Smyth; Lynsey Fazal; Ruth Feltell; Isobel Harada; Joe Coyle; Brian Williams; Matthias Reule; Hayley Angove; David M Cross; John Lyons; Nicola G Wallis; Neil T Thompson
Journal:  Cancer Sci       Date:  2012-02-09       Impact factor: 6.716

4.  Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia.

Authors:  Xose S Puente; Magda Pinyol; Víctor Quesada; Laura Conde; Gonzalo R Ordóñez; Neus Villamor; Georgia Escaramis; Pedro Jares; Sílvia Beà; Marcos González-Díaz; Laia Bassaganyas; Tycho Baumann; Manel Juan; Mónica López-Guerra; Dolors Colomer; José M C Tubío; Cristina López; Alba Navarro; Cristian Tornador; Marta Aymerich; María Rozman; Jesús M Hernández; Diana A Puente; José M P Freije; Gloria Velasco; Ana Gutiérrez-Fernández; Dolors Costa; Anna Carrió; Sara Guijarro; Anna Enjuanes; Lluís Hernández; Jordi Yagüe; Pilar Nicolás; Carlos M Romeo-Casabona; Heinz Himmelbauer; Ester Castillo; Juliane C Dohm; Silvia de Sanjosé; Miguel A Piris; Enrique de Alava; Jesús San Miguel; Romina Royo; Josep L Gelpí; David Torrents; Modesto Orozco; David G Pisano; Alfonso Valencia; Roderic Guigó; Mónica Bayés; Simon Heath; Marta Gut; Peter Klatt; John Marshall; Keiran Raine; Lucy A Stebbings; P Andrew Futreal; Michael R Stratton; Peter J Campbell; Ivo Gut; Armando López-Guillermo; Xavier Estivill; Emili Montserrat; Carlos López-Otín; Elías Campo
Journal:  Nature       Date:  2011-06-05       Impact factor: 49.962

5.  Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia.

Authors:  J E Lancet; I Gojo; M Burton; M Quinn; S M Tighe; K Kersey; Z Zhong; M X Albitar; K Bhalla; A L Hannah; M R Baer
Journal:  Leukemia       Date:  2010-01-28       Impact factor: 11.528

6.  Evolution and impact of subclonal mutations in chronic lymphocytic leukemia.

Authors:  Dan A Landau; Scott L Carter; Petar Stojanov; Aaron McKenna; Kristen Stevenson; Michael S Lawrence; Carrie Sougnez; Chip Stewart; Andrey Sivachenko; Lili Wang; Youzhong Wan; Wandi Zhang; Sachet A Shukla; Alexander Vartanov; Stacey M Fernandes; Gordon Saksena; Kristian Cibulskis; Bethany Tesar; Stacey Gabriel; Nir Hacohen; Matthew Meyerson; Eric S Lander; Donna Neuberg; Jennifer R Brown; Gad Getz; Catherine J Wu
Journal:  Cell       Date:  2013-02-14       Impact factor: 41.582

7.  Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia.

Authors:  Víctor Quesada; Laura Conde; Neus Villamor; Gonzalo R Ordóñez; Pedro Jares; Laia Bassaganyas; Andrew J Ramsay; Sílvia Beà; Magda Pinyol; Alejandra Martínez-Trillos; Mónica López-Guerra; Dolors Colomer; Alba Navarro; Tycho Baumann; Marta Aymerich; María Rozman; Julio Delgado; Eva Giné; Jesús M Hernández; Marcos González-Díaz; Diana A Puente; Gloria Velasco; José M P Freije; José M C Tubío; Romina Royo; Josep L Gelpí; Modesto Orozco; David G Pisano; Jorge Zamora; Miguel Vázquez; Alfonso Valencia; Heinz Himmelbauer; Mónica Bayés; Simon Heath; Marta Gut; Ivo Gut; Xavier Estivill; Armando López-Guillermo; Xose S Puente; Elías Campo; Carlos López-Otín
Journal:  Nat Genet       Date:  2011-12-11       Impact factor: 38.330

Review 8.  The Hsp90 chaperone complex as a novel target for cancer therapy.

Authors:  M P Goetz; D O Toft; M M Ames; C Erlichman
Journal:  Ann Oncol       Date:  2003-08       Impact factor: 32.976

9.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.

Authors:  Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillaume Dighiero; Hartmut Döhner; Peter Hillmen; Michael J Keating; Emili Montserrat; Kanti R Rai; Thomas J Kipps
Journal:  Blood       Date:  2008-01-23       Impact factor: 22.113

10.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Authors:  John C Byrd; Richard R Furman; Steven E Coutre; Ian W Flinn; Jan A Burger; Kristie A Blum; Barbara Grant; Jeff P Sharman; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Juthamas Sukbuntherng; Betty Y Chang; Fong Clow; Eric Hedrick; Joseph J Buggy; Danelle F James; Susan O'Brien
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

View more
  4 in total

1.  Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance).

Authors:  Megan Li; Flora Mulkey; Chen Jiang; Bert H O'Neil; Bryan P Schneider; Fei Shen; Paula N Friedman; Yukihide Momozawa; Michiaki Kubo; Donna Niedzwiecki; Howard S Hochster; Heinz-Josef Lenz; James N Atkins; Hope S Rugo; Susan Halabi; William Kevin Kelly; Howard L McLeod; Federico Innocenti; Mark J Ratain; Alan P Venook; Kouros Owzar; Deanna L Kroetz
Journal:  Clin Cancer Res       Date:  2018-06-05       Impact factor: 12.531

2.  Traditional and Novel Mechanisms of Heat Shock Protein 90 (HSP90) Inhibition in Cancer Chemotherapy Including HSP90 Cleavage.

Authors:  Sangkyu Park; Jeong-A Park; Jae-Hyung Jeon; Younghee Lee
Journal:  Biomol Ther (Seoul)       Date:  2019-05-21       Impact factor: 4.634

3.  Anti-Trypanosoma cruzi Activity of Metabolism Modifier Compounds.

Authors:  Nieves Martinez-Peinado; Clara Martori; Nuria Cortes-Serra; Julian Sherman; Ana Rodriguez; Joaquim Gascon; Jordi Alberola; Maria-Jesus Pinazo; Alheli Rodriguez-Cortes; Julio Alonso-Padilla
Journal:  Int J Mol Sci       Date:  2021-01-12       Impact factor: 5.923

Review 4.  Chaperone-assisted E3 ligase CHIP: A double agent in cancer.

Authors:  Sunny Kumar; Malini Basu; Mrinal K Ghosh
Journal:  Genes Dis       Date:  2021-09-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.